Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma

BACKGROUND: The use of adjuvant chemotherapy (ACT) for stage IB lung adenocarcinoma remains controversial. We examined the benefits of ACT in stage IB patients with tumors composed of solid material. METHODS: The records of 309 patients with stage IB lung adenocarcinoma who had undergone complete re...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Shuhui, Teng, Jiajun, Xu, Jianlin, Han, Baohui, Zhong, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360240/
https://www.ncbi.nlm.nih.gov/pubmed/30561142
http://dx.doi.org/10.1111/1759-7714.12942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360240/
https://www.ncbi.nlm.nih.gov/pubmed/30561142
http://dx.doi.org/10.1111/1759-7714.12942

Ejemplares similares